Trial analysis evaluates MammaPrint utility for predicting extended letrozole therapy benefit in early-stage breast cancer, highlighting improved patient selection for endocrine therapy.
MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.
No takes yet. Share an insight, caveat, or question.
Rastogi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: